A biomarker is a quantifiable sign of a biological condition or state. In order to investigate typical biological processes, pathogenic processes, or pharmacologic reactions to a therapeutic intervention, biomarkers are frequently examined and studied utilizing blood, urine, or soft tissues. Numerous scientific disciplines employ biomarkers. There are 2 types of biomarkers actively used in the market, they are Biomarker test Kits and Biomarker Analyzer. A relatively new set of clinical toolsets organized by clinical applications includes biomarkers utilized in the medical industry.
Market Dynamics
Increasing product launch by market players is expected to drive the market growth over the forecast period. For instance, on April 19, 2021, Amgen Inc., a global biotechnology company that uses science and innovation to translate novel concepts and medical discoveries into treatments for patients with life-threatening illnesses, announced the launch of the Biomarker Assist program, which aims to provide access to biomarker testing for patients with metastatic (stage IV) non-small cell lung cancer (NSCLC). A crucial initial step in placing patients on the appropriate course of treatment is biomarker testing at the time of diagnosis. Eligible patients may receive discounts on biomarker testing through Biomarker Assist.
Furthermore, on February 28, 2022, an initiative program was launched by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium aims to find the most effective blood tests for assessing a protein that is crucial for the early detection of rare neurodegenerative illnesses. The "Neurofilament as a Fluid Biomarker of Neuro degeneration in Familial Front temporal Degeneration (FTD)" study will demonstrate that one or more blood tests for this protein, known as neurofilament, can be used to determine individuals at risk of Front temporal Degeneration (FTD) due to genetic and familial ties. This is a crucial first step in developing a trustworthy, affordable, and non-invasive method to more accurately predict Front temporal Degeneration (FTD). Also, those who are at threat can take part in clinical studies of novel specifics, eventually leading to the development of treatments.
Key features of the study:
- This report provides an in-depth analysis of the global biomarkers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global biomarkers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, strategies
- Key companies covered as a part of this study include Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Acobiom, Apis Assay Technologies Ltd., Eagle Biosciences, Inc., Beckman Coulter, Inc., PerkinElmer Inc., Biopanda Reagents Ltd, Quanterix, Secure Diagnostics Pvt. Ltd., BioVision Inc., Merck KGaA, R&D Systems, Life Diagnostics, QuantaMatrix Inc., Nanjing Synthgene Medical Technology Co., Ltd, LifeSpan BioSciences, Inc., Wako USA, BioLegend, Inc., Abnova Corporation, and Abbexa
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have an ease in decision-making through various strategy matrices used in analyzing the global biomarkers market
Detailed Segmentation:
- Global Biomarkers Market, By Product Type:
- Biomarker Test Kits
- Biomarker Analyzer
- Global Biomarkers Market, By Application:
- Diagnostic Biomarkers
- Monitoring Biomarkers
- Drug Discovery And Development
- Predictive Biomarkers
- Prognostic Biomarkers
- Global Biomarkers Market, By Disease Indication
- Cancer
- Cardiovascular Disease
- Neurological Disorder
- Infectious disease
- Others (Immunological Disorder, and Autoimmune Disorders among others )
- Global Biomarkers Market, By End User:
- Hospitals
- Research Laboratories
- Diagnostic Laboratories
- Research and Academic Institute
- Global Biomarkers market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Agilent Technologies, Inc. *
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- F.Hoffmann-La Roche Ltd.
- Acobiom
- Apis Assay Technologies Ltd.
- Eagle Biosciences, Inc.
- Beckman Coulter, Inc.
- PerkinElmer Inc.
- Biopanda Reagents Ltd
- Quanterix
- Secure Diagnostics Pvt. Ltd.
- BioVision Inc.
- Merck KGaA
- R&D Systems
- Life Diagnostics
- QuantaMatrix Inc.
- Nanjing Synthgene Medical Technology Co. Ltd
- LifeSpan BioSciences Inc
- Wako USA,
- BioLegend, Inc
- Abnova Corporation
- Abbexa
“*” marked represents similar segmentation in other categories in the respective section.
